Chinese expert consensus on the clinical management of immune-related adverse events in neoadjuvant immunotherapy for rectal cancer(2025 edition)
Chinese Society of Colorectal Surgery,Chinese Society of Surgery,Chinese Medical Association
Neoadjuvant Therapy for Rectal Cancer Professional Committee,Beijing Cancer Prevention & Treatment Society
LIN Guo-le
YAO Hong-wei
XU Yan
ZHANG Zhong-tao
Abstract：Rectal cancer is one of the most common malignant tumors worldwide, with both incidence and mortality rates ranking among the top in China's cancer statistics. The application of immune checkpoint inhibitors (ICIs) in neoadjuvant therapy for locally advanced rectal cancer has significantly improved treatment outcomes, with some patients achieving a pathological complete response (pCR) [1]. However, with the widespread use of ICIs, immune-related adverse events (irAEs) caused by them have gradually attracted attention.
Keywords：immune checkpoint inhibitorsneoadjuvant therapyrectal neoplasmsdrug toxicities
Publication Date：2025-09-01
Online Publishing Date：2025-10-22(First online date of this platform, not the publication date of the document)
Pages：10( 969-978 )